Chronic hepatitis delta cirrhosis cured by adapting PEG-IFNα-2a + tenofovir disoproxil fumarate treatment duration until HBsAg loss.
Chronic hepatitis delta
Cirrhosis
HBsAg loss
PEG-IFNα-2a
Tenofovir disoproxil fumarate
Journal
Clinics and research in hepatology and gastroenterology
ISSN: 2210-741X
Titre abrégé: Clin Res Hepatol Gastroenterol
Pays: France
ID NLM: 101553659
Informations de publication
Date de publication:
08 2023
08 2023
Historique:
received:
17
01
2023
revised:
25
05
2023
accepted:
25
05
2023
medline:
14
8
2023
pubmed:
28
5
2023
entrez:
27
5
2023
Statut:
ppublish
Résumé
As the loss of HBsAg during treatment of chronic hepatitis delta (CHD) is mandatory for definitive clearance and durable response, the optimal target of therapy should be complete response (CR), defined as loss of HDV RNA and HBsAg, plus development of anti-HBs. The optimal treatment duration of CHD is not well established. We present 2 cases of patients with CHD cirrhosis who were treated with prolonged Peg-IFNα-2a + tenofovir disoproxil fumarate until HBsAg loss, and who achieved CR after 46 and 55 months of treatment respectively. A personalized approach and prolonged treatment duration determined by HBsAg loss may increase the likelihood of CR in CHD.
Identifiants
pubmed: 37244588
pii: S2210-7401(23)00073-6
doi: 10.1016/j.clinre.2023.102148
pii:
doi:
Substances chimiques
Tenofovir
99YXE507IL
Hepatitis B Surface Antigens
0
Antiviral Agents
0
Hepatitis B e Antigens
0
DNA, Viral
0
Types de publication
Case Reports
Langues
eng
Sous-ensembles de citation
IM
Pagination
102148Informations de copyright
Copyright © 2023 Elsevier Masson SAS. All rights reserved.
Déclaration de conflit d'intérêts
Declaration of Competing Interest None.